Category Medical Robotics

MDAI emerged as a formal regulatory classification in June 2025, making it foundational early-stage standard for AI-enabled medical devices.

da Vinci's clinical dominance, consumables lock-in, and margin advantage created an insurmountable competitive moat that still holds despite well-funded rivals.

FDA approval and $150 million in federal funding position Spectral AI for explosive growth in a market expanding at 19% annually.

Intuitive Surgical controls 80% of robotic surgery, making surgeon lock-in its most durable competitive advantage.

Microbot Medical trades under $1 because clinical approval remains unproven and revenue is minimal while cash burn continues relentlessly.

MDAI is not the next Google of medical robotics, despite what the ticker symbol and marketing language might suggest.

Microbot Medical Inc. (NASDAQ: MBOT) is not the next Nvidia in the sense of semiconductor manufacturing, but it represents something equally...

Medical robotics could produce the next Nvidia because it's following the exact playbook that made Nvidia dominant in AI: become the foundational...

Intuitive Surgical (ISRG) functions as the dominant platform provider in surgical robotics much the same way NVIDIA dominates AI compute...